Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Curis (CRIS – Research Report). The associated price target remains the same with $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors surrounding Curis’s strategic advancements in the IRAK4 inhibitor space. The company’s focus on developing emavusertib for lymphoma and leukemia, particularly in primary CNS lymphoma (PCNSL), is a significant driver. The ongoing pivotal trial and the anticipated efficacy data update at ASH 2025 underscore Curis’s potential in this niche.
Additionally, the management’s plans to present biomarker data at ASCO/EHA 2025 and the enthusiasm expressed by investigators about the PCNSL data further bolster confidence in Curis’s approach. Despite challenges in patient enrollment, the company’s strategy to expand clinical sites and explore further development steps in the AML program, coupled with a solid cash position, supports the optimistic outlook. These elements collectively contribute to the Buy rating, reflecting Curis’s promising position in the healthcare sector.
Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Elicio Therapeutics, and Chimerix. According to TipRanks, Roy has an average return of -27.6% and a 15.15% success rate on recommended stocks.
In another report released on April 9, Truist Financial also maintained a Buy rating on the stock with a $0.00 price target.